Foretinib (GSK1363089): ATP-Competitive VEGFR and HGFR Inhibitor for Precision Cancer Research

Executive Summary: Foretinib (GSK1363089) is a small-molecule, ATP-competitive multikinase inhibitor with nanomolar potency against VEGFRs and HGFR/Met, validated in diverse in vitro and in vivo cancer models (Schwartz 2022). It directly inhibits MET, KDR (VEGFR2), Flt-1, Flt-4 (VEGFR3), KIT, Flt-3, PDGFR α/β, and Tie-2 with IC₅₀ values between 0.4–9.6 nmol/L. Foretinib suppresses tumor cell proliferation and motility, with maximum efficacy in cell-based assays at 21–23 nmol/L. It is insoluble in water/ethanol but dissolves at ≥31.65 mg/mL in DMSO; stocks should be stored at −20°C and used promptly. Foretinib is distributed for research use by APExBIO (product page).

Biological Rationale

Cancer cell proliferation and metastasis are driven by dysregulated receptor tyrosine kinase (RTK) signaling. Foretinib targets key RTKs implicated in tumor angiogenesis (VEGFRs), cell motility (HGFR/Met), and survival (PDGFRs, KIT, Flt-3). Inhibition of these pathways can arrest tumor progression and reduce metastatic potential (Schwartz 2022). The VEGF receptor signaling pathway is central to angiogenesis, while the HGF/Met axis governs invasive growth. By disrupting both, Foretinib enables comprehensive study of tumor biology and experimental therapeutics.

Mechanism of Action of Foretinib (GSK1363089)

Foretinib is an ATP-competitive inhibitor that binds the catalytic site of multiple RTKs. It exhibits high affinity for MET (HGFR), VEGFR2 (KDR), VEGFR3 (Flt-4), and additional kinases including Ron, KIT, Flt-3, PDGFR α/β, and Tie-2. IC₅₀ values for these targets range from 0.4 nmol/L (MET) to 9.6 nmol/L (Tie-2) under standardized biochemical conditions (APExBIO). In cellular assays, Foretinib blocks HGF-induced cell motility and induces G2/M cell cycle arrest, suppressing proliferation and migration of B16F10 melanoma, PC-3 prostate, A549 lung, and HT29 colon cancer cells. Inhibition of MET phosphorylation occurs at 21–23 nmol/L in these models.

Evidence & Benchmarks

• Foretinib inhibits MET, KDR/VEGFR2, Flt-1, Flt-4/VEGFR3, KIT, Flt-3, PDGFRα, PDGFRβ, and Tie-2 with biochemical IC₅₀ values between 0.4–9.6 nmol/L (APExBIO).
• Cellular MET inhibition is achieved at 21–23 nmol/L in B16F10, PC-3, A549, and HT29 cells (Schwartz 2022).
• Foretinib treatment induces G2/M arrest and decreases cell proliferation in multiple cancer lines (Schwartz 2022).
• In vivo, oral dosing at 30 mg/kg reduces metastatic tumor nodules and tumor weight in ovarian cancer xenograft models (APExBIO).
• Foretinib is highly soluble in DMSO (≥31.65 mg/mL) but insoluble in water/ethanol; recommended storage is −20°C (APExBIO).
• Fractional viability and cell proliferation are distinct readouts for Foretinib activity; both are affected in vitro (Schwartz 2022).

For practical assay design, see Optimizing Cancer Assays with Foretinib, which focuses on troubleshooting and workflow setup; this article extends those findings with mechanistic benchmarks from peer-reviewed sources.

Applications, Limits & Misconceptions

Foretinib is validated for use in:

• Cell viability, proliferation, and cytotoxicity assays across diverse tumor types.
• Motility and invasion assays measuring HGF-induced cell migration.
• In vivo xenograft studies for metastatic and primary tumor growth inhibition.
• Pathway dissection of VEGF, HGF/Met, and angiogenic signaling in preclinical models.

For advanced workflows, Foretinib: Multikinase Inhibitor for Precision Cancer Research offers troubleshooting and translational guidance; this current article provides updated IC₅₀ and target data verified as of 2024.

Common Pitfalls or Misconceptions

• Foretinib is not suitable for diagnostic or therapeutic clinical use; it is strictly for research applications (APExBIO).
• Compound is insoluble in water or ethanol; DMSO is required for reliable stock solutions.
• Prolonged storage at room temperature leads to degradation; stocks should be kept at −20°C and used promptly after dilution.
• Relative viability and fractional viability are not interchangeable and must be interpreted according to assay design (Schwartz 2022).
• Foretinib's efficacy is context-dependent and may vary with cell type, passage, and assay readout conditions.

For further troubleshooting, Foretinib: Reliable Multikinase Inhibition addresses practical lab challenges, while this article provides a mechanistic, evidence-based perspective.

Workflow Integration & Parameters

• Stock Preparation: Dissolve Foretinib at ≥31.65 mg/mL in DMSO; do not use water or ethanol.
• Storage: Store stock solutions at −20°C. Avoid repeated freeze-thaw cycles.
• Assay Concentrations: For MET inhibition, use 21–23 nmol/L in cell-based assays; titrate as required by cell line and endpoint (Schwartz 2022).
• In Vivo Models: Oral dosing at 30 mg/kg is validated for xenograft studies.
• Endpoints: Assess both cell proliferation (e.g., MTT, CellTiter-Glo) and cell death (e.g., Annexin V, PI exclusion) to capture the full drug response spectrum.
• Vendor: APExBIO supplies Foretinib (SKU A2974) for research use (product page).

Foretinib is best leveraged in integrated functional assays. For scenario-driven workflow design, see Foretinib: Multikinase Inhibitor for Cancer Mechanisms. This article supplements those protocols with machine-actionable, quantitative parameters and updated references.

Conclusion & Outlook

Foretinib (GSK1363089) is a potent, ATP-competitive VEGFR and HGFR/Met inhibitor, enabling reproducible dissection of tumor cell growth, migration, and metastasis mechanisms. Its nanomolar efficacy, broad kinase selectivity, and compatibility with in vitro and in vivo models make it a cornerstone tool for mechanistic cancer research. Updated evidence confirms its utility in pathway-targeted studies, while product-specific handling parameters ensure experimental reproducibility. As a research reagent, Foretinib exemplifies the intersection of target validation, mechanistic insight, and workflow optimization in preclinical oncology. For detailed protocols and troubleshooting, refer to APExBIO's product documentation and the referenced peer-reviewed literature.